Henry Schein Inc. has named a former LabCorp executive to head its global dental group, the Melville-based company announced Tuesday.
The executive, Jonathan Koch, was named senior vice president and chief executive of the global dental group, working at corporate headquarters, effective immediately.
Koch, 43, formerly was an executive at the Covance drug development unit of Laboratory Corp. of America (LabCorp), a Burlington, North Carolina-based health care diagnostics company.
Koch also will serve as a member of the company's executive management committee.
The company also announced that James P. Breslawski, 64, was named vice chairman of the company in addition to his role as president of Henry Schein.
Breslawski, a 38-year veteran of the company and a member of the executive management committee, was CEO of the global dental group from 2005 to March 2018, the company said.
He has had a seat on the board of directors since 1992.
Koch, who will oversee sales, distribution, marketing, operations, technology and business development, will report to Breslawski.
"Jon's mission is to build upon the great work done by Jim . . . and to accelerate the growth of our dental business globally," Stanley M. Bergman, chairman and CEO of Henry Schein, said in a statement.
"Health care markets globally are experiencing tremendous change and offer significant opportunities for agile participants, making this an exceptional time to join Henry Schein," Koch said.
Henry Schein, Long Island's largest public company by revenue and market capitalization, distributes supplies to the office-based practices of dentists and physicians.
Shares of Henry Schein rose 1.1 percent Tuesday to close at $76.87. The stock is down about 12 percent in the past 12 months.